BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34378541)

  • 1. An optimized BRD4 inhibitor effectively eliminates NF-κB-driven triple-negative breast cancer cells.
    Yang GJ; Song YQ; Wang W; Han QB; Ma DL; Leung CH
    Bioorg Chem; 2021 Sep; 114():105158. PubMed ID: 34378541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA.
    Zou Z; Huang B; Wu X; Zhang H; Qi J; Bradner J; Nair S; Chen LF
    Oncogene; 2014 May; 33(18):2395-404. PubMed ID: 23686307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indole-2-Carboxamide Derivative LG25 Inhibits Triple-Negative Breast Cancer Growth By Suppressing Akt/mTOR/NF-κB Signalling Pathway.
    Xu X; Rajamanickam V; Shu S; Liu Z; Yan T; He J; Liu Z; Guo G; Liang G; Wang Y
    Drug Des Devel Ther; 2019; 13():3539-3550. PubMed ID: 31631978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling.
    Wu X; Qi J; Bradner JE; Xiao G; Chen LF
    J Biol Chem; 2013 Dec; 288(50):36094-105. PubMed ID: 24189064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA.
    Huang B; Yang XD; Zhou MM; Ozato K; Chen LF
    Mol Cell Biol; 2009 Mar; 29(5):1375-87. PubMed ID: 19103749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth.
    Ren C; Zhang G; Han F; Fu S; Cao Y; Zhang F; Zhang Q; Meslamani J; Xu Y; Ji D; Cao L; Zhou Q; Cheung KL; Sharma R; Babault N; Yi Z; Zhang W; Walsh MJ; Zeng L; Zhou MM
    Proc Natl Acad Sci U S A; 2018 Jul; 115(31):7949-7954. PubMed ID: 30012592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy.
    Zhang J; Tang P; Zou L; Zhang J; Chen J; Yang C; He G; Liu B; Liu J; Chiang CM; Wang G; Ye T; Ouyang L
    J Med Chem; 2021 Dec; 64(24):18025-18053. PubMed ID: 34908415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
    Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
    Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
    Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
    Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
    J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
    Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
    Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia.
    Feng Z; Chen A; Shi J; Zhou D; Shi W; Qiu Q; Liu X; Huang W; Li J; Qian H; Zhang W
    Bioorg Chem; 2021 Jun; 111():104849. PubMed ID: 33798846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors.
    Xu Y; Zhang XJ; Li WB; Wang XR; Wang S; Qiao XP; Chen SW
    Eur J Med Chem; 2020 Dec; 208():112780. PubMed ID: 32883643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
    Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
    J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
    Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
    Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-pot three-component synthesis of novel spirooxindoles with potential cytotoxic activity against triple-negative breast cancer MDA-MB-231 cells.
    Eldehna WM; El-Naggar DH; Hamed AR; Ibrahim HS; Ghabbour HA; Abdel-Aziz HA
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):309-318. PubMed ID: 29281924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative.
    Zhang J; Chen P; Zhu P; Zheng P; Wang T; Wang L; Xu C; Zhou J; Zhang H
    Bioorg Chem; 2020 Jun; 99():103817. PubMed ID: 32361153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways.
    Zhang Y; Xu B; Shi J; Li J; Lu X; Xu L; Yang H; Hamad N; Wang C; Napier D; He S; Liu C; Liu Z; Qian H; Chen L; Wei X; Zheng X; Huang JA; Thibault O; Craven R; Wei D; Pan Y; Zhou BP; Wu Y; Yang XH
    Cell Oncol (Dordr); 2020 Dec; 43(6):1049-1066. PubMed ID: 33006750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.